Lyka Labs Limited — Updates, 08-04-2025: Press Release

Lyka Labs Limited has secured an Indian Patent for its innovative product, Pregabalin Gel 8%, which is designed for managing diabetic neuropathic pain. This patent, valid until 2043, underscores Lyka's commitment to advancing topical drug delivery systems. Pregabalin Gel 8% is a unique formulation that offers localized pain relief while minimizing systemic side effects commonly associated with oral medications. Following its regulatory approval from the Central Drugs Standards Control Organization (CDSCO) in October 2024, the gel was launched in December 2024 through partnerships with Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare.

The patent strengthens Lyka's intellectual property portfolio and positions the company favorably within the pharmaceutical sector, focusing on addressing unmet medical needs for patients suffering from chronic conditions. Given this innovation, investors should watch closely for the potential growth opportunities arising from this strategic development.